RxDoctor Payments Data

Muhammad Ahmed, MD

Psychiatry · New Orleans, LANPI 1588724561

Payments from drug & device makers

$4,505in general payments, 2019–2025

Across 250 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$1K
  • Neurocrine Biosciences, Inc.$504
  • AbbVie$378
  • Indivior Inc.$373
  • Otsuka America Pharmaceutical, Inc.$369
  • Sunovion Pharmaceuticals Inc.$274
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$4,493100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,505 in reported general payments places this provider in the 85th percentile of 474 psychiatry providers in Louisiana.

See all psychiatry providers in Louisiana

Medicare billing

Part B allowed, 2024
$8,821
Medicare patients
24
Services billed
88

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl97$148,026
Invega TrinzaPaliperidone Palmitate18$134,849
Invega SustennaPaliperidone Palmitate23$78,343
AustedoDeutetrabenazine12$49,138
Abilify MaintenaAripiprazole11$33,959
LybalviOlanzapine/Samidorphan Malate13$20,958
VivitrolNaltrexone Microspheres12$19,395
Lurasidone Hcl110$11,002
Aripiprazole119$6,267
TrintellixVortioxetine Hydrobromide11$5,597
Clozapine27$3,387
Paliperidone ErPaliperidone32$2,970
Quetiapine Fumarate309$2,906
Haloperidol44$2,497
Ziprasidone Hcl36$2,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$244$213,19241 claims
AbbVieVraylar$378$148,02697 claims
Teva Pharmaceuticals USA, Inc.Austedo$205$49,13812 claims
Alkermes, Inc.Lybalvi, Vivitrol$1,252$40,35425 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$369$33,95911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 474 psychiatry providers in Louisiana.

Other psychiatry in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →